ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Dystonia
- Essential Tremor
- Holmes Tremor
- Huntington's Disease
- Movement Disorders
- Orofacial Dyskinesias
- Parkinson's Disease
- Tardive Dyskinesia
- Wilson's Disease
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided focused ultrasound thermal ablation of a designated area in the brain of patients suffering from movement disorder symptoms: FUS under MRI-guidance and MRI-based thermometry can be safely delivered to patient...
The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided focused ultrasound thermal ablation of a designated area in the brain of patients suffering from movement disorder symptoms: FUS under MRI-guidance and MRI-based thermometry can be safely delivered to patients suffering from treatment-refractory movement disorders through an intact human skull with a low risk of transient adverse effects as evaluated during follow-up of up to 12-months. A pre-defined target volume inside the brain can be accurately ablated, as demonstrated on post-treatment MRI. Lesions generated with ExAblate Neuro will result in clinical effects that are similar to those seen with ablative procedures using other surgical techniques (e.g. RF procedure).
Tracking Information
- NCT #
- NCT02252380
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Andres Lozano, MD Sunnybrook Health Sciences Centre
Get Well Soon